2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal 2Seventybio has announced a definitive merger agreement under which Bristol Myers Squibb (BMS) will acquire the company in an all-cash transaction for a total equity value of approximately US$ 286 million. The transaction has been

Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma in children and young adults. The transaction has been approved by both companies and is expected to close

Bluebird bio to be acquired by Carlyle and SK Capital According to report the company has been acquired for about US$30 million. Carlyle and SK Capital will provide primary capital to scale Bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.